Possible Ways of Pharmacological Correction of Ischemic Liver Damage

We are glad to introduce several variants of pharmacological correction of ischemic hepatic injury by three different types of medicines—incretinomimetics, imidazoline receptor’s agonists and biguanides. The study was conducted at the center for preclinical studies, Belgorod National Research University. The experiment was performed on both sex rats, divided into seven groups (n = 10): An intact group, pseudo-operated animals (autopsy of the abdominal wall without ligation of the liver vessels), ischemia/reperfusion group without drug correction, animals undergoing ischemia/liver reperfusion + metformin (50 mg/kg), animals undergoing ischemia/liver reperfusion + moxonidine (1 ?g/kg), animals undergoing ischemia/liver reperfusion + C7070 (10 mg/kg). For the evaluation, the coefficients calculated from the level of hepatic transaminases (ALT, AST), as well as morphometric ratios of the area of necrosis and deep ischemia of the liver, were used for evaluation according to the histological examination. The experiment was performed on 50 rats of both sexes, divided into the next groups (n = 10): An intact group; pseudo-operated animals (autopsy of the abdominal wall without ligation of the liver vessels), ischemia/reperfusion group without drug correction, animals undergoing ischemia/liver reperfusion + metformin (50 mg/kg), animals undergoing ischemia/liver reperfusion + moxonidine (1 ?g/kg), animals undergoing ischemia/liver reperfusion + C7070 (10 mg/kg), animals undergoing ischemia/liver reperfusion + vildagliptine (0.2 mg/kg), animals undergoing ischemia/liver reperfusion + exenatide (10 ?g/kg). For the evaluation, the coefficients calculated from the level of hepatic transaminases (ALT, AST), as well as morphometric ratios of the area of necrosis and deep ischemia of the liver, were used for the evaluation according to the histological examination. Conclusion The imidazoline receptor agonists significantly and significantly reduce the functional and morphological manifestations of liver ischemia/reperfusion.